Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.
about
Recognizing Potential Buprenorphine Medication Misuse: Product Packaging Does Not Degrade With Laundering.A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence.Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participantsLong-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden."Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.Buprenorphine Prescribing: To Expand or Not to ExpandClinician beliefs and attitudes about buprenorphine/naloxone diversionAddressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience.Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.Perceptions and practices addressing diversion among US buprenorphine prescribers.MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study
P2860
Q30300304-AF3917DF-268F-4E35-A0B8-C6D97C49C2ACQ34253036-AE4AF16E-2DDE-470C-AB81-D020043AD153Q34543555-E2366047-24B4-4C19-B185-1ED6CE7BAAB8Q34602727-CE3225A6-65B1-4E98-B156-564D501C9A50Q35109559-96BD8EF3-6DF5-4A4A-9DA2-BCAC7A8D8725Q35923078-6E769474-0530-41C2-9D43-AA79022F30C7Q36855631-C0FEAE63-CB99-411B-B0F5-6D7F4B5756CFQ37241381-F97280CD-96F1-4DF6-9529-B17A45105852Q38618111-746D4DA2-DBEE-4B62-8878-505515D70373Q38691415-1E5CDE64-DE7A-4C7B-AFCA-BF13366D57FDQ52316798-7E85D011-BE60-40F2-A16D-7B8732A782A8Q58700874-8A1E7D3C-B257-4877-953A-1B52F5954FA3
P2860
Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inability to access buprenorph ...... using diverted buprenorphine.
@ast
Inability to access buprenorph ...... using diverted buprenorphine.
@en
type
label
Inability to access buprenorph ...... using diverted buprenorphine.
@ast
Inability to access buprenorph ...... using diverted buprenorphine.
@en
prefLabel
Inability to access buprenorph ...... using diverted buprenorphine.
@ast
Inability to access buprenorph ...... using diverted buprenorphine.
@en
P2860
P1476
Inability to access buprenorph ...... r using diverted buprenorphine
@en
P2093
Michelle R Lofwall
P2860
P304
P356
10.1016/J.DRUGALCDEP.2012.05.025
P577
2012-06-15T00:00:00Z